Silence Therapeutics plc
SLNCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $43,258 | $25,375 | $17,501 | $12,415 |
| % Growth | 70.5% | 45% | 41% | – |
| Cost of Goods Sold | $11,810 | $10,318 | $10,880 | $7,456 |
| Gross Profit | $31,448 | $15,057 | $8,192 | $4,959 |
| % Margin | 72.7% | 59.3% | 46.8% | 39.9% |
| R&D Expenses | $67,883 | $44,025 | $35,605 | $30,765 |
| G&A Expenses | $26,884 | $26,222 | $25,682 | $20,008 |
| SG&A Expenses | $26,884 | $26,222 | $25,682 | $20,008 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$10,300 | -$10,900 | $0 |
| Operating Expenses | $94,767 | $64,661 | $55,214 | $50,773 |
| Operating Income | -$63,319 | -$49,604 | -$48,593 | -$45,814 |
| % Margin | -146.4% | -195.5% | -277.7% | -369% |
| Other Income/Exp. Net | $18,855 | -$706 | $1,225 | -$42 |
| Pre-Tax Income | -$44,464 | -$50,310 | -$47,368 | -$45,856 |
| Tax Expense | $845 | -$7,043 | -$6,879 | -$6,446 |
| Net Income | -$45,309 | -$43,267 | -$40,489 | -$39,410 |
| % Margin | -104.7% | -170.5% | -231.4% | -317.4% |
| EPS | -0.33 | -0.49 | -0.52 | -0.44 |
| % Growth | 32.7% | 5.8% | -18.2% | – |
| EPS Diluted | -0.33 | -0.49 | -0.52 | -0.44 |
| Weighted Avg Shares Out | 138,752 | 111,277 | 96,585 | 88,950 |
| Weighted Avg Shares Out Dil | 138,752 | 111,277 | 96,585 | 88,950 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,472 | $1,446 | $280 | $13 |
| Interest Expense | $0 | $34 | $47 | $11 |
| Depreciation & Amortization | $593 | $498 | $482 | $427 |
| EBITDA | -$48,989 | -$49,778 | -$50,624 | -$45,421 |
| % Margin | -113.2% | -196.2% | -289.3% | -365.9% |